Schizophrenia

Once-Monthly Perseris Approved for the Treatment of Schizophrenia

By July 30, 2018

Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.

Aristada Initio Regimen Approved for Initiation of Schizophrenia Treatment

By July 02, 2018

Prior to this approval, the Aristada initiation regimen consisted of taking oral aripiprazole for 21 consecutive days starting with the first Aristada dose.

Substance Use Disorders Linked to Conversion to Schizophrenia

April 26, 2018

This prospective cohort study included a population-based sample of 2,539 individuals born in Denmark with an incident diagnosis of schizotypal disorder and without a previous diagnosis of schizophrenia.

FDA Grants Fast Track Status to Lumateperone for Schizophrenia

By November 20, 2017

In two studies, lumateperone showed a statistically significant separation from placebo on the primary endpoint, the Positive and Negative Syndrome Scale, or PANSS, total score.

Antipsychotic Efficacy Compared in Real-World Schizophrenia Study

June 09, 2017

Risk of rehospitalization substantially lower with long-acting injectables versus oral equivalents